Protease-activated receptor 3 and uses thereof

Details Protease-activated receptor 3 and uses thereof Protease-activated receptor 3 and uses thereof

2007-02-13

2007-02-13

Pak, Michael (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

09208629

ABSTRACT:
Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis. Antibodies specific for a protease-activated receptor 3 (or receptor fragment or analog) and their use as a therapeutic are also disclosed.

REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5686597 (1997-11-01), Coleman et al.
patent: 5688768 (1997-11-01), Coughlin et al.
patent: 5759994 (1998-06-01), Coughlin et al.
patent: 5798248 (1998-08-01), Coughlin et al.
patent: 5849507 (1998-12-01), Coughlin
patent: 5856448 (1999-01-01), Coughlin
patent: 5892014 (1999-04-01), Coughlin et al.
patent: 5976841 (1999-11-01), Wnedt et al.
patent: 6024936 (2000-02-01), Coughlin et al.
patent: 6111075 (2000-08-01), Xu et al.
patent: 6124101 (2000-09-01), Coughlin
patent: 6197541 (2001-03-01), Coughlin
patent: 6436400 (2002-08-01), Xu et al.
patent: 0 712 934 (1996-05-01), None
patent: WO 95/03318 (1995-02-01), None
patent: WO 95/19436 (1995-07-01), None
patent: WO-96/40040 (1996-12-01), None
patent: WO-96/40040 (1996-12-01), None
patent: WO-98/18456 (1998-05-01), None
patent: WO-98/31810 (1998-07-01), None
patent: WO-98/31810 (1998-07-01), None
patent: WO-99/43809 (1999-09-01), None
patent: WO-99/43809 (1999-09-01), None
patent: WO 99/50415 (1999-10-01), None
Amatruda III, T.T. et al. (1991) “Gα16, a G protein α subunit specifically expressed in hematopoietic cells,”Proc. Natl. Acad. Sci.88:5587-91.
Connolly, A., et al., (1996). “Role of the thrombin receptor in development and evidence for a second receptor,”Nature 381:516-519.
Ishii, K., et al. (1993) “Kinetics of thrombin receptor cleavage on intact cells,”J. Biol Chem. 268:9780-9786.
Ishii, K., et al. (1995) “Determinants of thrombin receptor cleavage,”J. Biol. Chem. 270:16345-16440.
Julius, D., et al., (1988) “Molecular characterization of a functional cDNA encoding the serotonin lc receptor,”Science 241:558-564.
Liu, L., et al. (1991) “The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity,”J. Biol. Chem. 266:16977-16980.
Mathews, I.I., et al. (1994) “Crystallographic structures of thrombin complexed with thrombin receptor peptides: Existence of expected and novel binding modes,”Biochem. 33:3266-3279.
Nanevicz, T., et al.. (1996) “Thrombin receptor activating mutations,”J. Biol. Chem. 271:702-706.
Nystedt, S., et al. (1994) “Molecular cloning of a potential proteinase activated receptor,”Proc. Natl. Acad. Sci. USA, 91:9208-9212.
Scarborough, R.M., et al. (1992) “Tethered ligand agonist peptides,”J. Biol. Chem. 267:13146-13149.
Soifer, S.J., et al. (1993) “Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development,”Am. J. Pathol. 144:60-69.
Vu, T.-K.H., et al. (1991) “Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation,”Cell 64:1057-1068.
Vu, T.-K.H., et al. (1991) “Domains specifying thrombin-receptor interaction,”Nature 353:674-677.
Ishihara et al., (1997). “Protease-activated receptor 3 is a second thrombin receptor in humans,”Nature386:502-506.
Kahn, M. et al. (Aug. 1998). “A Dual Thrombin Receptor System for Platelet Activation,”Nature394:690-694.
Nanevicz, T. et al. (1995). “Mechanisms of Thrombin Receptor Agonist Specificty: Chimeric Receptors and Complementary Mutations Identify an Agonist Recognition Site,”J. Biol. Chem.270(37):21619-21625.
Soifer, S. et al. (1993). “Thrombin Receptor Structure and Function,”J. Cell. Biochem. Suppl.(17 Part D) p. 191.
Database Genebank, (Jan. 1, 1997), Accession No. AA177828, Marra, M. et al. ‘The WashU-Merck EST Project’, .
Bohm, S. et al. (1996). “Molecular Cloning, Expression and Potential Functions of the Human Proteinase-Activated Receptor-2,”Biochem. J.314(3):1009-1016.
Chen, J. et al. (Oct. 1995). “Tethered Ligand Library for Discovery of Peptide Agonsts,”J. Biol. Chem.270(40):23398-23401.
Coughlin, S. et al. (1992). “Expression Cloning and Characterization of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation,”Semin. Thrombin. Hemos.18(2):161-166.
Coughlin, S. et al. (1992). “Thrombin Receptor Structure and Function,”Cold Spring Harb. Symp. Quant. Biol.57:149-154.
Coughlin, S. (Sep. 1994). “Protease-Activated Receptors Start a Family,”Proc. Natl. Acad. Sci. USA91:9200-9202.
Gerszten, R. et al. (Apr. 1994). “Specificity of the Thrombin Receptor for Agonist Peptide by its Extracellular Surface,”Nature368(6472):648-651.
Gronke, R. et al. (1987). “Thrombin Interaction with Platelets Influence of Platelet Protease Nexin,”J. Boil. Chem.262(7):3030-3036.
Harmon, J. and Jamieson, G. (1985). “Thrombin Binds to a High-Infinity Approximately 900000-Dalton Site on Human Platelets,”Biochem.24(1):58-64.
Kahn et al. (Sep. 1998). “Gene and Locus Structure and Chromosomal Localization of the Protease-Activated Receptor Gene Family,”J. Biol. Chem.273(36):23290-23296.
Adams, R.L.P. (1980)Laboratory Techniques in Biochemistry and Molecular Biology.Work, T.S. et al., eds. Elsevier, New York, NY, five pages. (Table of Contents only.).
An, S. et al. (1997). “Identification of cDNAs Encoding Two G Protein-Coupled Receptors for Lysosphingolipids,”FEBS Lett.417(3):279-282.
Ausubel, F.M. et al. (1989).Current Protocols in Molecular Biology. John Wiley and Sons, New York, NY, seven pages. (Table of Contents only.).
Brass, L.F. et al. (Jun. 8, 1997). “Thrombin Receptors on Human Platelets: Initial Localization and Subsequent Redistribution During Platelet Activation,”Throm. Haem., XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, Jun. 6-12, 1997, p. 63 (Abstract No. PS-255).
Chen, J. et al. (Jun. 10, 1994). “Thrombin Receptor Activation: Confirmation of the Intramolecular Tethered Liganding Hypothesis and Discovery of an Alternative Intermolecular Liganding Mode,”J. Biol. Chem.269(23):16041-16045.
Chou, P. Y. et al. (1978). “Empirical Predictions of Protein Conformation,”Ann. Rev. Biochem.47:251-276.
Connolly, T.M. et al. (Oct. 1994). “Species Variability in Platelet and Other Cellular Responsiveness to Thrombin Receptor-Derived Peptides,”Thromb. Haemost.72(4):627-633.
Connolly, A.J. et al. (Nov. 1997). “Mice Lacking the Thrombin Receptor, PAR1, Have Normal Skin Wound Healing,”Amer. J. Path.151(5):1119-1204.
Coughlin, S.R. (Jul. 31, 1997). “Thrombin Signaling in Vivo,”FASEB J.11(9):A1452 (Abstract No. 3483).
Coughlin, S. (Oct. 21, 1997). “How Thrombin Talks to Cells: Molecular Mechanisms and Rolesin Vivo,” Circ.96(8 Suppl.):I-F.
Coughlin, S.R. et al. (Oct. 1994). “Molecular Mechanisms of Thrombin Signaling,”Sem. in Hemat.31(4):270-277.
Coughlin, S.R. et al. (Feb. 1992). “Characterization of a Functional Thrombin Receptor: Issues

Affiliated with

Also associated with

Rating

Protease-activated receptor 3 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protease-activated receptor 3 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease-activated receptor 3 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3884161